tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hypersensitivity D006967 22 associated lipids
Bacterial Infections D001424 21 associated lipids
Anemia D000740 21 associated lipids
Vomiting D014839 21 associated lipids
Hyperglycemia D006943 21 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Translocation, Genetic D014178 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
HIV Infections D015658 20 associated lipids
Ataxia D001259 20 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Brain Edema D001929 20 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Albuminuria D000419 18 associated lipids
Down Syndrome D004314 18 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Ischemia D007511 18 associated lipids
Dermatomycoses D003881 17 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Hemorrhage D006470 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Vasculitis D014657 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Alopecia D000505 14 associated lipids
Stomatitis D013280 14 associated lipids
Corneal Diseases D003316 13 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Critical Illness D016638 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Hypoglycemia D007003 13 associated lipids
Biliary Fistula D001658 13 associated lipids
Urticaria D014581 13 associated lipids
Hypercalcemia D006934 13 associated lipids
Listeriosis D008088 12 associated lipids
Osteoporosis D010024 12 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Skin Neoplasms D012878 12 associated lipids
Eye Diseases D005128 12 associated lipids
Crohn Disease D003424 12 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Keloid D007627 12 associated lipids
Hypertension, Portal D006975 12 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Retinoblastoma D012175 12 associated lipids
Shock D012769 11 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Thinness D013851 11 associated lipids
Shock, Septic D012772 11 associated lipids
Nephrotic Syndrome D009404 11 associated lipids
Dehydration D003681 11 associated lipids
Influenza, Human D007251 11 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Exanthema D005076 11 associated lipids
Hyperpigmentation D017495 11 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Cosio FG et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. 2007 Transplantation pmid:17318073
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Castells L et al. Liver transplantation in HIV-HCV coinfected patients: a case-control study. 2007 Transplantation pmid:17297413
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Sulanc E et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. 2005 Transplantation pmid:16249743
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Hanto DW and Chudzinski R What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? 2009 Transplantation pmid:19155968
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Egli A et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. 2013 Transplantation pmid:23274966
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Letavernier E et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. 2005 Transplantation pmid:16314786
Wai LE et al. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. 2008 Transplantation pmid:18192925
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238